Your browser doesn't support javascript.
loading
[Integration of Inventory Data from Cohort and Registry Studies into an Existing Research Network: National Pandemic Cohort Network (NAPKON)]. / Integration von Bestandsdaten aus Kohorten- und Registerstudien in ein existierendes Forschungsnetzwerk: Nationales Pandemie Kohorten Netz (NAPKON).
Hofmann, Anna-Lena; Vehreschild, Jörg Janne; Witzenrath, Martin; Hoffmann, Wolfgang; Illig, Thomas; Schreiber, Stefan; Anton, Gabriele; Hellmuth, Johannes Christian; Muenchhoff, Maximilian; Scherer, Clemens; Pley, Christina; Thibeault, Charlotte; Kurth, Florian; Berger, Sarah; Hummel, Michael; Hopff, Sina Marie; Stecher, Melanie; Appel, Katharina; Stahl, Dana; Kraus, Monika; Lorenz-Depiereux, Bettina; Hanß, Sabine; von Kielmansegg, Sebastian; Schlünder, Irene; Niemeyer, Anna; Heuschmann, Peter; Krawczak, Michael; Reese, Jens-Peter.
Afiliação
  • Hofmann AL; Universität Würzburg, Institut für klinische Epidemiologie und Biometrie, Würzburg, Germany.
  • Vehreschild JJ; Goethe-Universität Frankfurt am Main, Abteilung für Innere Medizin 2, Hämatologie/Onkologie, Frankfurt am Main, Germany.
  • Witzenrath M; Universität zu Köln, Medizinische Fakultät und Universitätsklinikum Köln, Germany.
  • Hoffmann W; Deutsches Zentrum für Infektionsforschung (DZIF), Partnerstandort Bonn-Köln, Köln, Germany.
  • Illig T; Charite Universitätsmedizin Berlin, Klinik für Pneumologie, Beatmungsmedizin und Intensivmedizin mit dem Arbeitsbereich Schlafmedizin, Berlin, Germany.
  • Schreiber S; Deutsches Zentrum für Lungenforschung (DZL), Standort Berlin, Berlin, Germany.
  • Anton G; Universität Greifswald, Institut für Community Medicine, Greifswald, Germany.
  • Hellmuth JC; Medizinische Hochschule Hannover, Hannover Unified Biobank, Hannover, Germany.
  • Muenchhoff M; Universitätsklinikum Schleswig-Holstein, Klinik Innere Medizin I, Kiel, Germany.
  • Scherer C; Helmholtz Zentrum München Institute of Epidemiology, Institut für Epidemiologie, Neuherberg, Germany.
  • Pley C; Deutsches Zentrum für Infektionsforschung eV Standort München, Standort München, Germany.
  • Thibeault C; Universitätsklinikum LMU München, Medizinische Klinik III, München, Germany.
  • Kurth F; Universitätsklinikum, LMU München, COVID-19 Register der LMU München (CORKUM), München, Germany.
  • Berger S; Universitätsklinikum, LMU München, COVID-19 Register der LMU München (CORKUM), München, Germany.
  • Hummel M; Nationales Referenzzentrum für Retroviren, LMU München, Max von Pettenkofer Institut & Genzentrum, Virologie, München, Germany.
  • Hopff SM; Universitätsklinikum, LMU München, COVID-19 Register der LMU München (CORKUM), München, Germany.
  • Stecher M; Universitätsklinikum, LMU München, Medizinische Klinik und Poliklinik I, München, Germany.
  • Appel K; Charité Universitätsmedizin Berlin, Clinical Trial Office, Berlin, Germany.
  • Stahl D; Charite Universitätsmedizin Berlin, Klinik für Pneumologie, Beatmungsmedizin und Intensivmedizin mit dem Arbeitsbereich Schlafmedizin, Berlin, Germany.
  • Kraus M; Charité Universitätsmedizin Berlin, Klinik für Pneumologie, Beatmungsmedizin und Intensivmedizin mit dem Arbeitsbereich Schlafmedizin, Berlin, Germany.
  • Lorenz-Depiereux B; Charité Universitätsmedizin Berlin, Department of Infectious Diseases, Respiratory Medicine and Critical Carein, Berlin, Germany.
  • Hanß S; Charité Universitätsmedizin Berlin, Zentrale Biobank (ZeBanC), Berlin, Germany.
  • von Kielmansegg S; Universität zu Köln, Medizinische Fakultät und Universitätsklinikum Köln, Abteilung I für Innere Medizin, Zentrum für Integrierte Onkologie Aachen Bonn Köln Düsseldorf, Köln, Germany.
  • Schlünder I; Uniklinik Köln Klinik I für Innere Medizin, Onkologie, Hämatologie, Klinische Infektiologie, Klinische Immunologie, Hämostaseologie, Internistische Intensivmedizin, Köln, Germany.
  • Niemeyer A; Deutsches Zentrum für Infektionsforschung (DZIF), Standort Köln-Bonn, Köln, Germany.
  • Heuschmann P; Goethe-Universität Frankfurt, Frankfurt am Main, Abteilung für Innere Medizin 2, Hämatologie/Onkologie, Frankfurt, Germany.
  • Krawczak M; Universitätsmedizin Greifswald, Unabhängige Treuhandstelle, Greifswald, Germany.
  • Reese JP; DZHK e.V. (Deutsches Zentrum für Herz-Kreislauf-Forschung), DZHK e.V. (Deutsches Zentrum für Herz-Kreislauf-Forschung), Greifswald, Germany.
Gesundheitswesen ; 2024 Aug 22.
Article em De | MEDLINE | ID: mdl-39173676
ABSTRACT
In the early phase of the COVID-19 pandemic, many local collections of clinical data on patients infected with SARS-CoV-2 were initiated in Germany. As part of the National Pandemic Cohort Network (NAPKON) of the University Medicine Network, the "Integration Core" was established to design the legal, technical and organisational requirements for the integration of inventory data into ongoing prospective data collections and to test the feasibility of the newly developed solutions using use cases (UCs). Detailed study documents of the data collections were obtained. After structured document analysis, a review board evaluated the integrability of the data in NAPKON according to defined criteria. Of 30 university hospitals contacted, 20 responded to the request. Patient information and consent showed a heterogeneous picture with regard to the pseudonymised transfer of data to third parties and re-contact. The majority of the data collections (n=13) met the criteria for integration into NAPKON; four studies would require adjustments to the regulatory documents. Three cohorts were not suitable for inclusion in NAPKON. The legal framework for retrospective data integration and consent-free data use via research clauses (§27 BDSG) was elaborated by a legal opinion by TMF - Technology, Methods and Infrastructure for Networked Medical Research, Berlin. Two UCs selected by the NAPKON steering committee (CORKUM, LMU Munich; Pa-COVID-19, Charité- Universitätsmedizin Berlin) were used to demonstrate the feasibility of data integration in NAPKON by the end of 2021. Quality assurance and performance-based reimbursement of the cases were carried out according to the specifications. Based on the results, recommendations can be formulated for various contexts in order to create technical-operational prerequisites such as interoperability, interfaces and data models for data integration and to fulfil regulatory requirements on ethics, data protection, medical confidentiality and data access when integrating existing cohort data. The possible integration of data into research networks and their secondary use should be taken into account as early as the planning phase of a study - particularly with regard to informed consent - in order to maximise the benefits of the data collected.

Texto completo: 1 Base de dados: MEDLINE Idioma: De Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: De Ano de publicação: 2024 Tipo de documento: Article